BioPorto Successfully Completes Private Placement of Shares
BioPorto A/S, a pioneering in vitro diagnostics company, has made a significant leap forward by successfully completing the private placement of 25,000,000 new shares. This strategic move has yielded gross proceeds of DKK 33.5 million, marking a pivotal step in accelerating its growth mission while enhancing the capabilities in early detection of Acute Kidney Injury (AKI).
CEO Commentary on the Private Placement
Peter Mørch Eriksen, CEO of BioPorto, expressed his gratitude towards the investors, stating, “I am delighted by the strong commitments from both our largest existing shareholders and new investors drawn to our company and the investment case.” He emphasized the inspiring support that empowers the company’s growth strategy, highlighting their commitment to advancing clinical trials targeting FDA clearance for the ProNephro AKI™ NGAL test in the United States.
Details of the Share Placement
The total subscription price for the new shares amounts to DKK 33,505,000, with payment expected by the end of the month. Following the payment, the registration of the share capital increase will occur promptly, and BioPorto aims to have the new shares listed on Nasdaq Copenhagen no later than the end of the month. This move reinforces BioPorto's commitment to expanding its market presence and optimizing shareholder value.
About BioPorto's Innovative Solutions
BioPorto is dedicated to developing actionable biomarkers for early diagnosis and patient management in healthcare. The company focuses on conditions with urgent medical needs and is particularly renowned for its NGAL biomarker, which plays a vital role in the assessment and diagnosis of AKI. By leveraging advanced antibody and assay development capabilities, BioPorto continuously aims to improve clinical outcomes and economic sustainability within health systems.
Cutting-Edge Technology in AKI Detection
The company’s flagship products, based on the NGAL biomarker, enable healthcare professionals to assess the risk of AKI early, significantly improving the potential for timely interventions. This allows for a more tailored approach to patient management, which is crucial given the severe consequences associated with delayed AKI diagnosis.
Global Reach and Commitment to Quality
With operations in Copenhagen and Boston, BioPorto not only maintains a robust research and development pipeline but also markets their NGAL tests across numerous markets worldwide. Following applicable registrations, including CE marks, their products stand out in the diagnostic landscape, positioning BioPorto as a leader in renal diagnostics.
Continuing Developments and Future Focus
Looking ahead, BioPorto is set to explore further financing options as they continue their strategy of growth and innovation. This will not only drive the development of new clinical trials but also enhance their commercial platform to better meet market demands.
Frequently Asked Questions
What was the outcome of the private placement by BioPorto?
The private placement was fully subscribed, raising DKK 33.5 million for the company.
How will the funds from the private placement be used?
The funds will be directed towards financing clinical trials for FDA clearance of the ProNephro AKI NGAL test and to strengthen their commercial capabilities.
What is the significance of the NGAL biomarker for BioPorto?
The NGAL biomarker is critical for early detection and assessment of Acute Kidney Injury, helping to enhance patient management and outcomes.
Who is the CEO of BioPorto and what did they say about investor support?
Peter Mørch Eriksen is the CEO, who expressed deep gratitude for the backing received from both existing and new investors, essential for the company's strategic growth.
Where can updates about BioPorto be found?
Updates can be received through BioPorto’s investor contact page, where you can sign up for announcements and other company-related information.
